Company intelligence / Profile preview

TheraCour Pharma

West Haven, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

TheraCour’s technology underpins several clinical candidates, including nanomedicine antivirals that have completed Phase 1 human trials for enveloped viral infections such as COVID-19 and herpesviruses; most programs are preclinical or IND-enabling, with ongoing advancement toward Phase 2 in lead candidates via licensee companies.[1][2][4]

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeNanoparticleNanomedicine
Industry: Biotech

Partnerships

NanoViricides (exclusive field licensee for human antiviral therapeutics)AllExcel (technology licensor)

Beyond the preview

Go deeper on TheraCour Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraCour Pharma.

Explore the full profile